Syringin exerts neuroprotective effects in a rat model of cerebral ischemia through the FOXO3a/NF-κB pathway

Int Immunopharmacol. 2021 Jan:90:107268. doi: 10.1016/j.intimp.2020.107268. Epub 2020 Dec 11.

Abstract

Inflammation plays an important role in the pathogenesis of cerebral ischemia. Syringin (SYR) is an active substance isolated from Acanthopanax senticosus plants, and possesses anti-inflammatory and neuroprotective properties. However, its effects on cerebral ischemic injury, as well as the underlying molecular events, are still unclear. The purpose of this study was to investigate the effect of SYR in a rat model of cerebral ischemia and address the related molecular mechanism. A middle cerebral artery occlusion/reperfusion model (MCAO) was used to simulate ischemic injury. SYR treatment clearly reduced the infarct volume, decreased cerebral water content, improved the neurological score, and attenuated neuronal death. Moreover, SYR decreased the expression of NF-κB, IL-1β, IL-6, TNF-α, and MPO, promoted FOXO3a phosphorylation and cytoplasmic retention, and inhibited the nuclear translocation of NF-κB. FOXO3a knockdown by RNA interference significantly prevented SYR-induced inhibition of NF-κB-mediated inflammation. Confocal microscopy revealed that SYR reduced NF-κB translocation to the nucleus, and FOXO3a silencing reversed this effect. Finally, immunofluorescence and CO-IP experiments showed that SYR promoted the interaction between FOXO3a and NF-κB. In conclusion, SYR exerted a protective effect against brain I/R injury by reducing the inflammation accompanying cerebral ischemia. This effect was mediated by the FOXO3a /NF-κB pathway.

Keywords: FOXO3a; Inflammation; NF-κB; Stroke; Syringin.

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • Body Water / metabolism
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / genetics
  • Cell Death / drug effects
  • Cytokines / metabolism
  • Forkhead Box Protein O3 / drug effects*
  • Glucosides / pharmacology*
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / pathology
  • Male
  • NF-kappa B / drug effects*
  • Neurons / pathology
  • Neuroprotective Agents / pharmacology*
  • Phenylpropionates / pharmacology*
  • Phosphorylation
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects*

Substances

  • Cytokines
  • FOXO3 protein, rat
  • Forkhead Box Protein O3
  • Glucosides
  • NF-kappa B
  • Neuroprotective Agents
  • Phenylpropionates
  • syringin